Navigation Links
Study shows combination of immune substances to be safe

New research has shown that the immune-stimulating hormone known as interleukin-12 (IL-12) can safely be administered with interferon, another immune-system protein, as an experimental therapy for some cancers.

Normally, interferon is used alone to stimulate the immune system to attack certain cancers. This strategy, a form of immunotherapy, is sometimes used to treat melanoma, advanced kidney cancer and other tumors that respond poorly to chemotherapy or radiation therapy. But interferon can have serious side effects that limit its use.

Surprisingly, the two drugs used in sequence caused no serious side effects in patients.

"Interferon can be quite toxic when used alone," says principal investigator William E. Carson, III, associate professor of surgery and associate director for clinical research at the Ohio State University Comprehensive Cancer Center.

"We were initially concerned that the addition of IL-12 might increase that toxicity. Instead, we found that the two drugs can be used together without additional side effects."

The findings are published in the December 1 issue of the Journal of Clinical Oncology. They suggest that IL-12 primes white blood cells such that a lower dose of interferon will stimulate the same level of immune activity as a higher dose of interferon when used alone.

The results come from a phase-I clinical trial, which marks the first time a treatment is tried in human subjects. The trial, conducted by Carson and a team of colleagues, involved 49 patients ages 23 to 84 with different types of advanced cancer, including cancers of the colon, lung, kidney and bladder and melanoma.

On the first day of treatment, patients were given IL-12, initially by injection and then intravenously. That was followed by injections of interferon over the next five days. On average, patients received five such cycles over the course of the study.

The drug combination not only proved to be safe ?which was the purpose of the study ?but the researchers found that it stopped disease progression in five of the patients for at least six months.

"Our findings were encouraging," Carson says. "They indicate that we can safely administer IL-12 in combination with interferon, that it enhances the action of interferon in some patients with advanced cancer, and that it can be an effective way to stimulate the immune system."

Based on the study's results, and the results of earlier animal studies led by the research group, Carson and his colleagues are conducting a multicenter phase II clinical trial of the two drugs in people with melanoma.

Phase-II trials are the first step in determining the effectiveness of new therapy against a specific disease.

"We believe that use of the two drugs together will give us more bang for the buck," says first author Gregory B. Lesinski, a research assistant professor in the Human Cancer Genetics Program.

"We hope that the IL-12 will allow us to use lower doses of interferon in patients, which should result in fewer side effects and potentially a longer use of interferon, giving the immune system more time to fight the tumor."


'"/>

Source:Ohio State University


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/20/2017)... 2017 Delta (NYSE: DAL ) customers now can ... at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan ... Delta,s biometric boarding pass experience that ... now integrated into the boarding process to allow eligible Delta SkyMiles Members ...
(Date:5/23/2017)... -- Hunova, the first robotic gym for the rehabilitation and functional motor sense ... Genoa, Italy . The first 30 robots will be available ... USA . The technology was developed and patented at the IIT ... Movendo Technology thanks to a 10 million euro investment from entrepreneur Sergio ... ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
Breaking Biology News(10 mins):
(Date:9/19/2017)... ... September 19, 2017 , ... ... (NYS DFS) cybersecurity regulations have transitioned into full force and effect. ... in the state (“Covered Entities”) to conduct an annual, professional, comprehensive cybersecurity ...
(Date:9/18/2017)... --  Montrium , a growing leader in Electronic Trial Master ... groundbreaking non-profit research organization, Multidisciplinary Association for Psychedelic Studies (MAPS). ... MAPS Public Benefit ... ... to MDMA for the treatment of Posttraumatic Stress Disorder (PTSD). MAPS ...
(Date:9/14/2017)... Lafayette, Ind (PRWEB) , ... ... ... of AMRI’s Global Analytical Services, formally introduces its flexible scientist program (FSP)-- ... offers volume-based, preferred-rate pricing. The FSP, which combines SSCI’s extensive project-based analytical ...
(Date:9/14/2017)... ... September 14, 2017 , ... AxioMed is pleased ... Australia. Dr. Steven Yang completed the procedure on a 35-year-old female patient suffering ... lumbar disc at level L5-S1. The patient failed conservative treatments prior to undergoing ...
Breaking Biology Technology: